A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.

MLA

Wu, Guang, et al. “A Novel Humanized MUC1 Antibody-Drug Conjugate for the Treatment of Trastuzumab-Resistant Breast Cancer.” Acta Biochimica et Biophysica Sinica, vol. 53, no. 12, Dec. 2021, pp. 1625–39. EBSCOhost, https://doi.org/10.1093/abbs/gmab141.

APA

Wu, G., Li, L., Qiu, Y., Sun, W., Ren, T., Lv, Y., Liu, M., Wang, X., Tao, H., Zhao, L., Cao, J., He, L., Li, H., & Gu, H. (2021). A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer. Acta Biochimica et Biophysica Sinica, 53(12), 1625–1639. https://doi.org/10.1093/abbs/gmab141

Chicago

Wu, Guang, Lan Li, Yuxin Qiu, Wei Sun, Tianhao Ren, Yingshuai Lv, Mengnan Liu, et al. 2021. “A Novel Humanized MUC1 Antibody-Drug Conjugate for the Treatment of Trastuzumab-Resistant Breast Cancer.” Acta Biochimica et Biophysica Sinica 53 (12): 1625–39. doi:10.1093/abbs/gmab141.